incidence of thrombotic events was noted to be 0.26% in a large multicenter medical record review (3) . Researchers noted that thrombosis was more common in those patients with opportunistic illnesses, those taking megestrol acetate or indinavir, and in those who have been hospitalized, as well as in older patients (older than 45 years of age). In a retrospective review of HIV patients with deep venous thromboses (DVT) admitted to the Mount Sinai School of Medicine/Cabrini Hospital in New York (4), the incidence of thrombotic events was 0.95% from 1995 to 2000. Also, a significant proportion of these patients with DVT had either an active infection or malignancy. In another retrospective review of patients admitted to the Long Island College Hospital from July 1, 1998 to June 30, 1999 (5) , the incidence of thrombotic events was 2.8% in HIV-positive patients. The incidence was 3.31% in those younger than 50 years old vs. 0.53% in those 50 Center (6) found 7.6% (10 of 131) HIV-infected patients with an unexplained DVT or pulmonary embolism (PE). The majority of the thrombotic events occurred in those with CD4 counts less than 200/mm 3 , and those with the concurrent presence of opportunistic infections or acquired immunodeficiency syndrome (AIDS)-related neoplasms. Thus thrombosis is a significant and probably under-recognized complication of HIV infection. A variety of hemostatic abnormalities have been identified in patients with HIV infection that provide mechanisms for a hypercoagulable state and increased likelihood of thrombosis. Best known are the endothelial-related changes that include the presence of antiphospholipid-anticardiolipin antibodies and microangiopathic changes. Less well publicized are a variety of changes in the physiologic anticoagulant system as a result of HIV infection. Decreased anticoagulant activities due to deficiencies in protein S, protein C, antithrombin, and heparin cofactor II, as well as decreased fibrinolysis due to increased levels of plasminogen activator inhibitor have been well described (7) . These coagulation abnormalities have been correlated with the CD4 count. It has been proposed that these changes are largely the result of disseminated intravascular coagulopathy and endothelial injury/activation (8) . Supporting this hypothesis is a report from Erbe and colleagues (9) that documented an increased incidence of deficiencies in both protein C (25%) and protein S (67%) in HIV-infected patients with an acute opportunistic infection, when compared to 8% and 54%, respectively, on follow-up investigations after the acute event.
Protein S deficiency is the most consistently observed coagulation abnormality in HIV-infected patients. The prevalence is reported to be as high as 76% (10, 11) . Some investigators (12, 13) have shown a correlation between low protein S levels and low CD4 counts, while others (10,11) have not. The prevalence of protein S deficiency (both total and functional) was greater in those with CD4 counts less than 200/mm 3 compared to those with CD4 counts above 200/mm 3 (11) . The relationship between protein S levels and CD4 counts may simply be a reflection of the duration of the HIV infection (10, 11) . While small case series have reported thrombotic events in protein S-deficient HIV patients, Hassell and colleagues (14) did not find a correlation between protein S deficiency and thrombosis. It must be concluded that the significance of low protein S levels in HIV-infected patients is indeterminate.
The frequency of protein S alterations/deficiencies has led to an extensive pursuit of potential mechanisms. Protein S is synthesized by the endothelium, hepatocytes, and megakaryocytes. Endothelial injury in HIV infection (15, 16) has been proposed as a reasonable etiologic basis for the decreased protein S in HIV-infected patients. Because free protein S is reduced in inflammatory states largely due to increased levels of C4bbinding protein, one would expect increased C4b-binding protein in HIV-infected patients. However, Stahl and colleagues (10) examined this issue and found no difference in the C4bbinding protein among normal controls, HIV patients with protein S deficiency, and HIV patients with normal protein S levels. Sugarman and coworkers (11) also failed to establish a relationship between protein S values and C4b-binding protein in HIV-infected children.
However, anti-protein S antibody has been noted to be more prevalent in the symptomatic HIV-infected patients, and in those HIV-infected patients who had protein S levels below 50% of normal (12) . In addition, increasing IgG anticardiolipin antibody level was correlated with decreasing levels of free protein S antigen in adults (10) . This relationship was not identified in children (11) . Despite the data in children, a working hypothesis that increased protein S clearance occurs secondary to autoimmune antibodies may be operative in the high prevalence of protein S deficiency in HIV-infected patients.
Another potential mechanism of the hypercoagulable state relates to platelet activation. Soluble P-selectin, a marker of platelet activation, is also noted to be elevated in HIV-infected patients and may contribute to the thrombotic tendency (17, 18) . Schecter and colleagues (19) reported that the HIV envelope protein, gp120, activates human arterial smooth muscle cells to express tissue factor, the initiator of the coagulation cascade. The activation of smooth muscle cells by gp120 may play an important role in the prothrombotic phenotype of the HIVinfected patients.
In two of the epidemiologic studies of thrombosis in HIV-infected patients (3, 6) , the use of protease inhibitors was associated with thrombotic events. Sullivan and colleagues (3) found that patients taking indinavir have an adjusted odds ratio of 2.4 (95% CI, 1.4-4.3) for the development of PE or DVT. A review of the literature by Saif and colleagues (6) found 45 HIV-infected patients with thrombotic events; 11 of the 45 were taking at least one protease inhibitor.
Among these 11 patients, portal vein thrombosis developed in two that led to portal hypertension and variceal bleeding. The offending medication was indinavir, and no bleeding was observed after the protease inhibitor was discontinued (20) . An interesting suggestion by these authors (6) was that because aspartyl proteases such as renin, endothelin, and cathepsin D are involved in the regulation of coagulation (21, 22) , and because the HIV protease is an aspartyl protease, inhibition of the proteases by indinavir may lead to a prothrombotic state. Further support for this comes from Henry and colleagues (23) , who reported two young patients in whom severe coronary artery occlusion developed after starting protease inhibitors. In addition, the 26-year-old patient (included in the Saif review) had angina 4 weeks after starting ritonavir and saquinavir. These authors did suggest that lipodystrophy due to the protease inhibitors was the cause of the premature coronary artery disease; however, the short duration of the therapy would suggest that other mechanisms are involved.
George and colleagues reviewed the other seven patients in the Saif review (24) . DVT or PE developed in seven of 650 HIV-infected patients after January 1, 1996; and, it is noteworthy that protease inhibitors were not available before that time. The mean time to the development of venous thromboembolism was 72 days after starting a protease inhibitor. No patient had a concurrent infection at the time of the thrombotic event. Three patients required high doses of warfarin to maintain a therapeutic International Normalized ratio, and the same three patients had recurrent thrombosis or extension of thrombosis while on warfarin and the protease inhibitor. One patient had a history of thrombosis (before institution of the protease inhibitor); one had recent surgery but was ambulatory for 9 weeks; one was obese and had increased anticardiolipin antibodies; one had a family history of DVT and also had increased anticardiolipin antibodies; one other patient had a family history of PE and was also taking hormonal replacement therapy. These data can be compared to historical controls before 1996, where only two cases of unexplained DVT were identified in 1050 patients. The estimated odds ratio for thromboembolism in the protease inhibitor-treated group was 5.7 (95% CI, 1.2-27, p<0.01) (24). Saif and colleagues (6) speculated that because the protease inhibitors are metabolized by the cytochrome P450 system, they may interfere with hepatic regulation of the thrombotic proteins, leading to a prothrombotic state in some patients. However, Pulik and colleagues (25) reported, in abstract form, the results of coagulation studies in non-hemophiliac HIV-infected patients treated with protease inhibitors. There were no changes in activated partial thromboplastin time, prothrombin time, fibrinogen, von Willebrand factor antigen, ristocetin cofactor activity, factor VIII activity, or factor XI antigen.
Majluf-Cruz and colleagues performed a retrospective study of their HIV-infected patients (26) . Similar to the study by George and colleagues (24) , the prevalence of venous thromboembolism appeared to have increased significantly since the protease inhibitors were introduced into clinical practice. In addition, they found a high incidence of protein S deficiency in this particular patient cohort. However, only functional protein S activity was examined; antigenic protein S was not determined. While previous studies we reviewed have established a quantitative deficiency of protein S, additional data on C4b-binding protein and protein S antigen would have been informative. Majluf-Cruz and colleagues also reported two patients who had acquired transient activated protein C resistance. It would have been interesting to know the factor VIII activity at the time of the acquired activated protein C resistance because elevated factor VIII can consume the activated protein C added for the assay and result in a falsely defined abnormality. Elevated factor VIII activity, which can be a result of acute phase reaction, is associated with an increased risk of thrombosis (27) . Information on the comorbidities at the time of the thrombotic events is also lacking, which may aid in the understanding of thrombophilia in the HIV-infected population.
An interesting aspect of the Majluf-Cruz report (26) is that the use of aspirin in this cohort of thrombophilic patients resulted in no further episodes of thrombosis, including those patients who had recurrent thromboses while taking oral anticoagulants. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study group recently reported its prospective observational study on the effects of combination antiretroviral therapy on the risk of myocardial infarction (28) . The incidence of myocardial infarction increased with longer exposure to combination antiretroviral therapy, with an adjusted relative rate per year of exposure of 1.26 (95% CI, 1.12-1.41).
These observations, along with the P-selectin studies (17, 18) , lend credence to the suggestion that platelet activation is an important patho-physiologic mechanism of the prothrombotic state in HIV-infected patients. To date, there are little formative data on the effect of protease inhibitors on platelet function. Such data might provide a basis for aspirin use as part of the primary therapy for HIV-infected patients with thrombophilia, particularly those placed on therapy with protease inhibitors.
Clearly a hypercoagulable state and thromboses are emerging as clinical issues in HIV-infected patients. Although commonly multi-factorial issues are projected as the clinical basis and the focus turns to management, the recent growing evidence of associated thrombophilia and correlated platelet activation as well as potential interactions with therapy with protease inhibitors all pose an important need to serially examine these aspects to more clearly delineate the pathophysiologic mechanism(s) of thromboses.
